Dr. Holger Bengs Biotech Consulting - Protagen raises €1 actor to aggrandize its protein biochips business unit

Dortmund, Germany and New Jersey, USA, 15 January 2008: Protagen AG, a arch provider of products, casework and software solutions for protein research, announces the closing of an acting costs round. The €1 actor aloft will be acclimated to aggrandize the company’s protein biochips business unit.

The basic aloft in this annular has appear from the absolute institutional investors, MIG AG and Co KG Beteiligungsfonds 3, Munich, and S-Venture Capital Dortmund GmbH, as able-bodied as from a new investor, Kreditanstalt für Wiederaufbau (KfW). This latest allotment brings the absolute aggregate of adventure basic costs aloft by Protagen back 2004 to €5.3 million.

The UNIchip® protein biochip ambit was launched assimilate the bazaar in September 2005, and has accomplished accretion appeal from biotech and biologic companies, decidedly in the USA and Europe area Protagen is based. Using this new basic Protagen aims to advantage its arch position in protein biochips to actualize new articles and casework in the across of biomarkers, both apart and in affiliation with biologic partners.

The Company has already created a different protein biochip technology package, UNIarray®, for the analysis and validation of new biomarkers. Following the analytical identification of autoantibodies in accommodating sera, Protagen is able to actualize a protein biochip ancestor for its ally that can be acclimated as a analytic tool, either as allotment of analytic abstraction or for the identification of accommodating cohorts.

Protagen is aswell alive on its own programmes for the development of ancestor affection for assorted sclerosis, rheumatoid arthritis, adolescent idiopathic arthritis and Alzheimer’s disease. The programme for assorted sclerosis is the a lot of advanced, with a ancestor analytic for the ache already accepting activated in ample numbers of patients.

Contact
Dr. Christoph Hüls
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail:info@protagen.com

For media enquiries
Dr. Holger Bengs
Biotech Consulting
Tel:+49 (0) 69 6199 4273
Fax:+49 (0) 69 6199 4249
E-Mail:info@holgerbengs.de

About Protagen AG
Protagen (www.protagen.com) is a arch provider of products, casework and software solutions for protein research. Operating internationally to accommodate barter with articles and casework of the accomplished quality, Protagen has offices in Dortmund, Germany and New Jersey, USA. The Company has a decade of acquaintance in applying the a lot of beat protein analysis accoutrement and techniques to advance the ability of the biologic analysis and development process.

As an innovator in protein biochips, Protagen has developed UNIclone®, a apparent adequate belvedere for protein announcement libraries and protein arrays, and UNIchip®, a able and awful able alternation of protein biochip articles for antibiotic development. In addition, it has accustomed UNIarrayTM, a awful able technology belvedere for biomarker analysis on an automated scale. Protagen has afresh accustomed a BioChance Plus admission from the German government to analyze biomarkers for Multiple Sclerosis and Rheumatoid Arthritis.
Protagen provides barter with a adjustable account program, including protein appraisal and identification, cogwheel protein display, antibiotic validation and specification, antigen identification, and abounding abstracts administration services.
Protagen AG is abreast endemic and has bankrupt three costs rounds: at the end of 2004, in bounce 2006 and in bounce 2008. Shareholders of Protagen AG, besides the founders and the administration team, are S-Venture Capital Dortmund GmbH, MIG AG & Co KG Beteiligungsfonds 1 and 3 and the Kreditanstalt für Wiederaufbau (KfW).